# Clinical Trial: REAL Parenting Alcohol and Substance Use App

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ced-sex-differences-in-analgesia-withdrawal-thera-2026-10-27/
> **Published:** 2026-10-27T11:18:57-04:00 | **Last Modified / Clinically Audited:** 2026-10-27T11:18:57-04:00
> **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan.

---

CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments.

Clinical Insight | CED Clinic
Cannabinoid research is shifting from simple efficacy studies toward personalized management strategies across distinct patient populations. Sex-dependent variations in cannabinoid metabolism and receptor density mean that men and women frequently report differing levels of pain relief and side effects from identical doses. Meanwhile, patients seeking to reduce or stop heavy cannabis consumption need evidence-based medical support to navigate severe withdrawal symptoms like sleep disruption and anxiety. Combining targeted withdrawal pharmacotherapy like PP-01 or synthetic cannabinoids with family-centered adolescent prevention software fills major gaps in clinical care, allowing physicians to offer structured, age-appropriate, and biologically tailored interventions.

DigestCannabis NewsRegulationPublic HealthClinical Practice

AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers.
Primary TopicClinical and policy analysis: Clinical Trial: REAL Parenting Alcohol and Substance Us.
Source[Read the full source](https://clinicaltrials.gov/study/NCT04385082)

Table of Contents

- [Clinical Trial: REAL Parenting Alcohol and Substance Use App](#Clinical_Trial_REAL_Parenting_Alcohol_and_Substance_Use_App)[How to Interpret This Cannabis News & Regulatory Digest](#How_to_Interpret_This_Cannabis_News_Regulatory_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Understanding Personal Responses to Cannabis](#Understanding_Personal_Responses_to_Cannabis)
- [Translating Research Into Personalized Dosing](#Translating_Research_Into_Personalized_Dosing)
- [Managing Withdrawal and Adolescent Risk Factors](#Managing_Withdrawal_and_Adolescent_Risk_Factors)
- [Public Health Frameworks for Regulation and Prevention](#Public_Health_Frameworks_for_Regulation_and_Prevention)
- [Advancing Methodological Rigor in Cannabinoid Science](#Advancing_Methodological_Rigor_in_Cannabinoid_Science)
- [Evaluating Limitations in Trial Registries and Data](#Evaluating_Limitations_in_Trial_Registries_and_Data)
- [Supporting Family Wellness and Safe Interventions](#Supporting_Family_Wellness_and_Safe_Interventions)
- [Synthesizing Biological Differences and Harm Reduction](#Synthesizing_Biological_Differences_and_Harm_Reduction)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

# Clinical Trial: REAL Parenting Alcohol and Substance Use App

A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research.

What This Study Teaches Us
Trial registries highlight active research into sex-dependent analgesic responses, pharmacological options for cannabis use disorder, and family-focused digital prevention tools. A completed UCLA Phase 1 trial evaluated sex differences in cannabinoid analgesia and abuse liability. Simultaneously, a Phase 3 trial is evaluating PP-01 against nabilone and placebo for withdrawal in moderate-to-severe CUD, while a digital app trial tested parent-based interventions to curb adolescent use.

Why This Matters
Understanding sex-specific responses helps clinicians tailor cannabinoid dosing and predict therapeutic efficacy for pain management. Developing validated pharmacological treatments for withdrawal and parent-led prevention apps provides structured clinical pathways for managing cannabis dependence across age groups.

Study SnapshotPost TypeCannabis News & Regulatory Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 27, 2026Related Reading3 verified live CED Clinic internal linksUpdate 1Cannabis Effects as a Function (University of California, Los Angeles Regulatory Analysis)Update 2Efficacy of PP-01 in Mitigating (PleoPharma, Inc. Regulatory Analysis)Update 3REAL Parenting Alcohol and Substance (Real Prevention, LLC Regulatory Analysis)

Clinical Bottom Line
This clinical and regulatory overview preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners.

Context Across These 3 Updates

This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report.

Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data.

Update 1: Cannabis Effects as a Function of Sex

**Title & Source:** [Clinical Trial: Cannabis Effects as a Function of Sex](https://clinicaltrials.gov/study/NCT04385082) (*University of California, Los Angeles*, 2026-10-27)

**Lead Authors & Identifiers:** University of California, Los Angeles. Content lane: **Clinical Evidence Update**.

**Regulatory Context:** This completed UCLA Phase 1 clinical trial investigated how biological sex influences the analgesic and abuse-related effects of cannabis. Researchers evaluated healthy human volunteers under controlled laboratory conditions to track physiological and subjective outcomes.

**Operative Findings:** The study protocol structured comparative testing between male and female cohorts following standardized cannabis administration. Primary outcomes focused on pain tolerance thresholds, subjective intoxication metrics, and physiological response markers.

**Clinical Relevance:** Clinicians should consider biological sex when evaluating patient sensitivity to cannabinoid analgesia and titration needs. Customizing initial doses based on sex-specific baseline responses minimizes unwanted psychoactive side effects.

**Practical Boundaries:** Phase 1 experimental studies feature small sample sizes and brief exposure periods that may not reflect long-term medical cannabis use. Results from controlled lab settings do not fully capture complex chronic pain conditions.

Update 2: Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms

**Title & Source:** [Clinical Trial: Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder](https://clinicaltrials.gov/study/NCT07644052) (*PleoPharma, Inc.*, 2026-10-27)

**Lead Authors & Identifiers:** PleoPharma, Inc.. Content lane: **Protocol Watch**.

**Regulatory Context:** This active Phase 3 multicenter trial evaluates the safety and efficacy of PP-01 in reducing withdrawal symptoms among adults with moderate to severe cannabis use disorder. The protocol uses a randomized, double-blind design comparing PP-01 against both placebo and active nabilone controls.

**Operative Findings:** The primary outcome measure tracks changes in standardized cannabis withdrawal scales over a multi-week intervention period. Secondary endpoints measure retention in treatment, craving scores, and successful cannabis abstinence rates.

**Clinical Relevance:** Physicians treating cannabis dependence should monitor emerging pharmacotherapies designed to ease withdrawal distress during cessation attempts. Structured withdrawal support can prevent early relapse in motivated patients seeking to stop daily use.

**Practical Boundaries:** The trial is currently recruiting, so final safety and efficacy data are not yet available for clinical application. Active-controlled designs can also face unblinding risks if side-effect profiles between test drugs and nabilone differ noticeably.

Update 3: REAL Parenting Alcohol and Substance Use App

**Title & Source:** [Clinical Trial: REAL Parenting Alcohol and Substance Use App](https://clinicaltrials.gov/study/NCT03932097) (*Real Prevention, LLC*, 2026-10-27)

**Lead Authors & Identifiers:** Real Prevention, LLC. Content lane: **Clinical Evidence Update**.

**Regulatory Context:** This completed trial evaluated the REAL Parenting mobile app, a digital health intervention designed to reduce alcohol, nicotine, and cannabis use among high school students. The project targeted parent-based communication strategies to diminish adolescent substance initiation and impaired driving risks.

**Operative Findings:** The evaluation analyzed parent engagement levels alongside adolescent self-reported substance use rates over multi-month follow-up intervals. Key measures included changes in parental boundary setting, teen risk perception, and driving passenger safety decisions.

**Clinical Relevance:** Healthcare providers addressing family wellness should consider mobile interventions that help parents initiate structured substance prevention conversations. Enhancing parent-child communication provides a protective layer against adolescent substance initiation.

**Practical Boundaries:** Substance use metrics rely on self-reported survey data, which carries inherent risks of underreporting or social desirability bias. Long-term durability of behavioral changes beyond the immediate post-intervention window remains unconfirmed.

How Strong Is This Evidence?
The evidence base across these registry listings spans early human experimental pharmacology to late-stage multicenter phase 3 trials and behavioral interventions. Phase 3 randomized, active-controlled designs evaluating withdrawal medications offer high internal validity, while early Phase 1 trials establish essential baseline pharmacokinetic and pharmacodynamic data. However, full peer-reviewed data and published outcome metrics remain necessary to confirm efficacy across diverse clinical settings.

Where This Paper Deserves Skepticism
Clinical trial registry listings reflect planned or completed protocol structures rather than verified, peer-reviewed outcome data. Methodological challenges in withdrawal trials include high attrition rates during active detoxification and difficulties maintaining double-blind conditions against active synthetic cannabinoids. Behavioral app trials targeting youth rely heavily on self-reported substance use data, which introduces recall and social desirability biases.

What This Paper Does Not Show
These registry entries do not establish definitive clinical efficacy for PP-01 or parent-based digital apps in real-world populations. They also do not prove that sex-dependent differences in cannabinoid response mandate entirely separate dosing guidelines in routine practice.

How This Fits With the Broader Clinical Conversation

The historical lack of standardized cannabinoid research frequently obscured critical sex-dependent differences in pain perception and abuse potential. Men and women exhibit distinct cannabinoid receptor density, circulating sex hormone interactions, and metabolic pathways for Delta-9-THC. Early Phase 1 research focusing specifically on these biological variations reflects a necessary shift toward precision medicine, ensuring that therapeutic protocols account for physiological differences.

At the same time, the medical management of cannabis use disorder has lacked widely approved pharmacological therapies, leaving clinicians reliant on unstandardized behavioral counseling. Evaluating targeted agents like PP-01 alongside active controls like synthetic nabilone in Phase 3 trials represents a major effort to standardize withdrawal treatment. Establishing structured clinical protocols for withdrawal symptoms addresses a primary driver of relapse among long-term, high-potency cannabis consumers.

Addressing adolescent substance use requires preventive measures that reach beyond traditional classroom instruction. Parent-based digital interventions attempt to leverage family dynamics to reduce teenage alcohol, nicotine, and cannabis exposure. Integrating mobile health tools into substance prevention frameworks creates an accessible method to mitigate adolescent risk factors before chronic dependence develops.

Editorial Commentary

*In clinical practice, observing how differently men and women respond to identical cannabinoid regimens is a constant reality. Hormonal fluctuations, body composition differences, and baseline endocannabinoid tone influence both pain relief and adverse effects. Recognizing these biological nuances allows clinicians to start with lower initial doses and adjust titration schedules tailored to individual physiology, avoiding excessive sedation or anxiety.*

*Patients attempting to pause or reduce heavy daily cannabis use often experience intense physical discomfort, including insomnia, irritability, and loss of appetite. Having validated, formal pharmaceutical options for withdrawal management would transform clinical addiction care, replacing ad-hoc symptomatic treatment with structured, evidence-grounded care plans. Pairing these medical tools with family-supported digital interventions offers a realistic, comprehensive spectrum of care from prevention to recovery.*

What a Careful Reader Should Take Away
Clinicians and patients should recognize that cannabinoid effects and withdrawal treatments are highly individualized and currently undergoing rigorous clinical testing. Evidence-based care requires adjusting regimens based on sex-specific responses while watching for validated medical therapies for cannabis use disorder.

[https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[💢Pain](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask)

Evidence Interpretation Guide

## How to Interpret This Cannabis News & Regulatory Digest

Understanding registry listings requires distinguishing active experimental protocols and trial designs from finalized clinical outcomes.

### Three Rules for Critical Reading

**Differentiate Phase 1 Mechanisms from Phase 3 Efficacy**Early Phase 1 trials explore basic human physiology like sex differences, whereas Phase 3 trials test clinical efficacy against placebos and active controls.

**Distinguish Protocol Registration from Peer-Reviewed Results**A registered trial on ClinicalTrials.gov confirms an active research effort, but clinical decisions require peer-reviewed data detailing primary endpoints.

**Evaluate Multimodal Approaches to Substance Management**Effective care plans combine biological understanding, targeted withdrawal pharmacotherapy, and behavioral support tools tailored to age and severity.

Key Evaluation Question
How do study designs isolate sex-specific physiological responses from behavioral and social confounding factors in cannabinoid research?

The Patient Question
Should my daily dose or choice of cannabinoid product differ based on my biological sex or previous experience with withdrawal symptoms?

The Bottom Line
Rigorous clinical trials are steadily replacing anecdotal assumptions with structured biological and therapeutic evidence across all aspects of cannabis medicine.

CED Perspective Lens

## CED Perspective Lens: Eight Viewpoints on These Updates

Why these developments matter across clinical, patient, safety, and policy perspectives

Lens OverviewEight distinct clinical and regulatory perspectives on Clinical Trial: REAL Parenting Alcohol and Su.

#### Understanding Personal Responses to Cannabis

Every person processes cannabis differently based on unique biological factors like sex and metabolic speed. Learning how biological sex influences pain relief and side effects helps patients set realistic expectations when starting therapy. Knowing that formal medical treatments for withdrawal are under development also gives hope to those wishing to reduce daily use.

If you notice that your response to a specific dose differs significantly from someone else, your biological sex and individual tolerance may play a central role. Working closely with a physician allows you to adjust doses safely, minimizing unpleasant side effects while achieving desired symptom management without distress.

Lens takeawayBiological sex influences how your body responds to cannabis, making personalized dosing guidance essential for safe symptom relief.

#### Translating Research Into Personalized Dosing

Clinicians frequently navigate wide variations in patient responses to standard cannabinoid formulations. Recognizing that male and female patients experience different analgesic thresholds and side-effect profiles enables more precise starting doses. Incorporating patient sex into clinical decision-making improves safety profiles and therapeutic compliance during initial titration.

In parallel, managing patients with severe cannabis use disorder requires structured, evidence-based withdrawal strategies. As Phase 3 trials progress on dedicated cessation drugs, physicians can prepare to offer medical withdrawal management alongside traditional cognitive behavioral support, providing comprehensive care for individuals seeking structured cannabis tapering.

Lens takeawayIncorporating sex-specific physiological responses into clinical protocols optimizes patient outcomes and minimizes therapy-induced adverse events.

#### Managing Withdrawal and Adolescent Risk Factors

Safety protocols in cannabis medicine must address both biological vulnerability and potential dependence. Abrupt cessation in long-term, high-potency users often triggers physical withdrawal, including insomnia, nausea, and mood disturbances. Formal pharmacological tools help stabilize patients, preventing relapse driven by severe physical discomfort during early abstinence periods.

Adolescent safety represents another critical concern where preventative digital tools show utility. Equipping parents with evidence-based communication apps reduces youth exposure to cannabis and alcohol. Preventing early adolescent initiation decreases the lifetime probability of developing severe substance dependence or experiencing impaired driving incidents.

Lens takeawayMitigating cannabis risks requires addressing physiological withdrawal in adult users while implementing structured prevention tools for adolescents.

#### Public Health Frameworks for Regulation and Prevention

Public health policies must balance therapeutic access with robust harm-reduction strategies. Federal trial registries demonstrate growing investment in evaluating dependence treatments and parent-focused youth prevention tools. Standardizing evidence-based therapies for cannabis use disorder strengthens state healthcare infrastructure as consumer access to high-potency products expands.

Regulators also benefit from sex-specific pharmacological research when establishing product labeling and consumer safety warnings. Clear, science-backed guidance regarding dosing differences between men and women enhances public safety standards while supporting well-regulated, evidence-based medical cannabis programs across healthcare systems. In clinical practice, evaluating policy factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayEffective cannabis policy requires funding research into dependence treatments, public education, and clear sex-differentiated dosing guidance.

#### Advancing Methodological Rigor in Cannabinoid Science

Research priorities are shifting from generalized observational surveys toward controlled experimental and Phase 3 clinical trials. Evaluating sex differences under standardized laboratory protocols isolates biological variables from environmental noise. These rigorous mechanistic studies establish the necessary foundation for tailored therapeutic guidelines and targeted drug delivery systems.

Simultaneously, Phase 3 trials testing novel withdrawal therapeutics against active synthetic controls set a higher bar for addiction medicine. Generating high-quality randomized trial data ensures that future clinical guidelines rely on validated primary endpoints rather than informal anecdotal reports.

Lens takeawayHigh-quality randomized trials isolating sex differences and withdrawal outcomes are essential to establishing gold-standard cannabis treatments.

#### Evaluating Limitations in Trial Registries and Data

Registry listings provide essential visibility into study designs, but they do not guarantee clinical success or published outcomes. Early Phase 1 trials on sex differences involve controlled settings that do not capture complex patient populations with chronic comorbidities or varied administration methods used in real-life scenarios.

In addition, behavioral intervention studies relying on self-reported youth substance use face inherent social desirability biases. In withdrawal trials, maintaining complete blinding remains challenging when active synthetic cannabinoids produce distinct subjective psychoactive signals that study participants easily recognize during trial protocols.

Lens takeawayCritical evaluation requires scrutinizing study blinding, self-report biases, and trial completion rates before accepting registry claims.

#### Supporting Family Wellness and Safe Interventions

Caregivers often serve as the primary line of defense against adolescent substance experimentation. Utilizing structured, app-based guidance empowers parents to hold effective, non-judgmental conversations regarding cannabis and alcohol safety. Early parent engagement helps teenagers make safer choices regarding peer pressure and vehicle passenger safety.

For caregivers supporting adult family members undergoing cannabis withdrawal, understanding that cessation involves real physical discomfort is vital. Recognizing withdrawal as a distinct medical phase allows caregivers to provide calm, empathetic environment support while encouraging loved ones to seek clinical medical supervision.

Lens takeawayEmpowering caregivers with structured communication tools and withdrawal education improves youth prevention and supports adult recovery efforts.

#### Synthesizing Biological Differences and Harm Reduction

Modern cannabis medicine is rapidly evolving toward personalized biological care and structured addiction support. Research isolating sex-specific pain responses highlights why uniform dosing guidelines are insufficient for optimal clinical care. Tailoring therapies to individual biological profiles improves therapeutic benefit while reducing adverse side effects.

Concurrently, advanced clinical trials for withdrawal management and youth prevention software demonstrate a comprehensive commitment to safety. Bridging gaps in patient management through validated pharmacotherapies and parent education ensures safer outcomes across every stage of life and treatment. In clinical practice, evaluating takeaway factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.

Lens takeawayA comprehensive approach combining sex-specific clinical dosing with validated withdrawal therapies and youth prevention builds safer cannabis medicine.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/)
 Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/)
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](http://CEDclinic.com/book)
 [Cannabis Care](http://CEDclinic.com/book)
 
 

 
 [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/)
 
 

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Clinical+Trial%3A+REAL+Parenting+Alcohol+and+Substance+Use+App&url=https%3A%2F%2Fcedclinic.com%2Fced-sex-differences-in-analgesia-withdrawal-thera-2026-10-27%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-sex-differences-in-analgesia-withdrawal-thera-2026-10-27%2F)
[BlueSky](https://bsky.app/intent/compose?text=Clinical+Trial%3A+REAL+Parenting+Alcohol+and+Substance+Use+App%20https%3A%2F%2Fcedclinic.com%2Fced-sex-differences-in-analgesia-withdrawal-thera-2026-10-27%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Primary Sources: University of California, Los Angeles, PleoPharma, Inc., Real Prevention, LLC](https://clinicaltrials.gov/study/NCT04385082)

Related Reading at CED ClinicContinue exploring the evidence[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)

More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling.

[More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)

More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal.

[More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)[Adolescent Cannabis Use and Its Impact on Cognitive Development: Insights from the ABCD Study](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)

More on this topic: Long-term ABCD study findings on adolescent brain development, executive function, and early cannabis susceptibility.

[More on this topic: Adolescent brain health](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)

## Frequently Asked Questions

What is covered in this cannabis news & regulatory digest?

This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science.

How are stories selected for CED digests?

Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians.

Do preliminary reports establish medical efficacy?

No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed.

How should clinicians use these updates?

Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling.

Where can readers find Dr. Caplan's clinical insights?

Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com.

Why are multi-topic digests published instead of single stories?

Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits.

What is the primary role of laboratory testing in cannabis policy?

Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health.

How do state regulatory milestones impact patient access?

Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care.

What precautions should families take with medical cannabis at home?

Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure.

How often does CED Clinic publish clinical and policy updates?

CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).